3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
3
Phase 3
2
Phase NA
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
3
Neoplasm Metastasis
2
Kidney Neoplasms
2
Urogenital Neoplasms
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
PRETEXT I Hepatoblastoma
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Breast Neoplasms
1
Interventions
Interferon-alpha
7
aldesleukin
6
Sunitinib
6
Radiotherapy
5
Nivolumab
5
Doxorubicin
5
Vincristine
4
Ipilimumab
4
Filgrastim
4
Dactinomycin
4
Chemotherapy, Adjuvant
4
Axitinib
4
cabozantinib
3
Sorafenib
3
Everolimus
3
Etoposide
3
Cyclophosphamide
3
temsirolimus
2
pembrolizumab
2
Ifosfamide
2
G250 monoclonal antibody
2
Fluorouracil
2
Carboplatin
2
Bevacizumab
2
vitespin
1
shark cartilage extract
1
pazopanib
1
lenvatinib
1
glutamic acid diethyl ester
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Kidney Neoplasms
×
temsirolimus
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts
NCT00065468
2012-10-25
ARCC
Pfizer
Phase 3
Completed
626 enrolled
18 charts